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Background. The conserved noncoding microRNAs (miRNAs) that function to regulate gene expression are essential for the
development and function of the brain and heart. Changes in miRNA expression proﬁles are associated with an increased risk
for developing neurodegenerative disorders as well as heart failure. Here, the hypothesis of how miRNA-regulated pathways could
contribute to comorbid neurological and cardiovascular disorders will be discussed. Presentation. Changes in miRNA expression
occurring in the brain and heart could have an impact on coexisting neurological and cardiovascular characteristics by (1)
modulating organ function, (2) accentuating cellular stress, and (3) impinging on neuronal and/or heart cell survival. Testing.
Evaluation of miRNA expression proﬁles in the brain and heart tissues from individuals with comorbid neurodegenerative and
cardiovascular disorders will be of great importance and relevance. Implications. Careful experimental design will shed light to the
deeper understanding of the molecular mechanisms tying up those diﬀerent but yet somehow connected diseases.
Copyright © 2009 S´ ebastien S. H´ ebert.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Background
In recent years, increasing evidence suggests that genetic and
epigenetic factors could be involved in disease comorbidity
[1–3]. On this line of thought, Lee et al. have identiﬁed
a common network of genes (and metabolic pathways)
that was altered in Alzheimer’s disease (AD) coinciding
with myocardial infarction (MI) [1]. Indeed, increased
activity of ACE and APOE genes, both involved in lipid
metabolism, was signiﬁcantly associated to the coexistence
of these disorders. Given the central role of the genome and
proteome in biology and pathobiology, it is safe to predict
thatmisregulationofspeciﬁcgeneexpressionnetworkscould
inﬂuence disease state and in some cases comorbidity.
Following the discovery of microRNAs (miRNAs) in
C. elegans more than a decade ago [4], research has majorly
evolved in order to gain insight of how the miRNA gene
network can have an impact on health and disease in
humans. Studies in animal models demonstrate that miRNA
genes are essential for life [5, 6], whereas changes in miRNA
expression proﬁles in humans are found in several diseases,
such as cancer [7]a sw e l la sn e u r o l o g i c a la n dc a r d i o v a s c u l a r
disorders (see below).
The miRNA gene family comprises a class of highly
conserved small (∼19–23nt) nonprotein-coding RNAs that
function in the cell to regulate gene expression at the
posttranscriptional level [6]. Like protein-coding genes,
miRNAs are embedded in the genome and generated by
a multistep process ([8] and references therein). The fully
processed mature miRNA molecule functions as part of the
RNA-induced silencing complex (RISC) and aﬀects gene
expression.Thisisachievedbybindingtothe3 UTRoftarget
messenger RNAs (mRNAs), leading to their translational
repression or degradation. Individual or families of miRNAs
can target up to several hundred mRNAs, thus controlling
complex gene expression pathways and biological systems
[9].
The role of miRNAs, in accordance with most biological
systems, has been best studied in development. Initial studies
inactivating Dicer, a type III RNase involved in miRNA
maturation (and therefore function), demonstrate that miR-
NAs are essential for life [10]. Tissue-speciﬁc deletion of
Dicer (and subsequently mature miRNAs) causes abnormal
brain and heart development in both Zebraﬁsh and mouse
[11–14]. Cell-speciﬁc functional roles for miRNAs in these
organsarealsoemerging.Indetail,thebrain-speciﬁcmiRNA2 Cardiovascular Psychiatry and Neurology
miR-134 is involved in dendritic spine formation as well as
in synaptic plasticity [15], while miR-124 [16]a n dm i R -
132 [17] are implicated in neurite outgrowth. In addition,
muscle-enriched miR-1 and miR-133 seem to control heart
muscle growth and diﬀerentiation [18, 19] and recently
shown to regulate muscle gene expression and inﬂuence
sarcomere assembly [20].
2. Presentationof the Hypothesis
Taking into account the growing evidence that miRNAs
are key regulators of gene expression and necessary for the
function and maintenance of all major biological systems,
it is reasonable to speculate that loss of the ﬁne-tuning
of this network could be relevant for the development
of comorbid diseases. One would therefore anticipate that
miRNA dysfunction occurs concomitantly (or in some
cases consecutively) in the brain and heart. Obviously,
nonautonomous eﬀects should not be ruled out, since they
could indirectly lead to changes in miRNA expression and
function.
Out of the known 706 human (547 mouse) miRNAs
(http://microrna.sanger.ac.uk),anabundantandparticularly
diverse group is expressed in the mammalian brain and heart
[21–25]. Several of these miRNAs are coexpressed in both
tissues (e.g., miR-29, let-7, miR-21, miR-103, miR-106, miR-
17-5p) at various relative levels of expression [22, 26–28].
Interestingly, a study by Kuhn et al. showed that a subset of
chromosome 21-derived miRNAs are overexpressed in both
the brain and heart tissues of down syndrome patients, thus
providing genetic proof-of-concept for the possibility that
speciﬁc miRNAs can be coregulated in these organs [29].
It is noteworthy that despite the fact that certain miRNAs
are likely more involved in tissue development (e.g., miR-
106,miR-17-5p)[30],theexpressionsofsomearespeciﬁcally
altered (either up- or downregulated) in disease or disease-
simulated conditions in mouse models and/or in humans.
Recent studies have indeed documented changes in the
levels of speciﬁc miRNAs in several major neurodegenerative
disorders including AD [27, 31], Huntington’s disease [32],
and Parkinson’s disease [33]. Alterations in miRNA levels
have been shown as well in various heart pathologies
including arrhythmia, cardiac ﬁbrosis, angiogenesis, and
cardiac hypertrophy (reviewed in [26, 34, 35]). Whether all
the reported changes in miRNA expression are involved in
respective diseases is doubtful (see below) but remains to be
explored.
Given recent ﬁndings, the hypothesis that speciﬁc vari-
ations in miRNA expression could play a signiﬁcant role
in comorbid neurological and cardiovascular pathologies
is attractive. Alterations of a single miRNA could have
profound eﬀects on hundreds of target genes [36, 37], thus
possibly implicating multiple biological pathways. However,
not all reported changes in miRNA expression would
necessarily be relevant to disease progression. Indeed, only a
few miRNAs could exert their regulatory function directly or
indirectly on disease-related genes, such as ACE and APOE.
Downregulation of miR-29 in AD brain as well as in
MI (commonly known as heart attack) is an appealing
example of how a speciﬁc miRNA (or miRNA family)
network could be involved in simultaneous existence of
neurological and cardiovascular pathological features. In
vitro and in vivo studies performed in the mouse heart have
shown that miR-29 (expressed mainly in cardiac ﬁbroblasts)
could regulate various collagens and other ECM proteins
involved in cardiac remodeling after MI [38]. In the brain,
it is suggested that miR-29 (expressed in both neurons and
glia) could contribute to the production of toxic amyloid-
β peptides by regulating BACE1/β-secretase [31]. Other
studies have shown that accumulation of amyloid-β peptides
causes degeneration of cells in the walls of blood vessels,
aﬀects vasoactivity, and improves proteolytic mechanisms,
such as ﬁbrinolysis, anticoagulation, and degradation of the
ECM [39]. Of notice, changes in the ECM are linked to
neurodegeneration[40]andmayplayaroleinADpathology
[41], whereas it is suggested that collagen levels could
modulate amyloid-β peptide toxicity in neurons [42]. Thus,
the combined action of miR-29 downregulation in the brain
a n dh e a r tc o u l dc o n t r i b u t et oad e t r i m e n t a lf e e d b a c kl o o p
between toxic amyloid-β production, changes in the ECM,
increased cellular stress, and ultimately cell dysfunction
and death. In this way, the collective eﬀects of miR-29
downregulation in the brain and heart could signiﬁcantly
increase the risk for MI in AD patients and perhaps be
involved in other comorbid neurological and cardiovascular
disorders (such as AD and congestive heart failure). It
should be noticed that the physiological role(s) of miR-
29, as with most miRNAs, remains unknown. Nonetheless,
it is safe to predict that changes in (single or numerous)
miRNA-regulated pathways may have multiple eﬀects on
numerous cellular and biological pathways involved in
neurological and cardiovascular physiology and pathophys-
iology, including apoptosis, lipid metabolism, and oxidative
stress.
3.Testing the Hypothesis
Simple studies can be performed to evaluate whether a
link between miRNA misexpression and neurological and
cardiovascular comorbidity exists. The ﬁrst step would be to
analyze global miRNA expression proﬁles from total RNA
isolated from the brain and heart tissues from (the same)
individuals with coinciding characteristics of neurodegen-
erative and cardiovascular disorders. Several miRNA gene
platforms (arrays) are commercially available. In this way, it
wouldbepossibletomaptheindividual(i.e.,brain-orheart-
speciﬁc) and shared (i.e., both organs) changes in miRNA
expression. Thus, heart and brain tissue banks for research
on cooccurring cardiovascular and neurological/psychiatric
disorders could be easily used for miRNA studies. Subse-
quentstepswouldbefocusedontheidentiﬁcationofmiRNA
target genes and pathways, ideally previously associated
with (respective or shared) disease(s). Several bioinformatics
logarithms for miRNA prediction sites in 3 U T Ro fg e n e s
are freely available online (Pictar, miRANDA, TargetScan,
etc.). Functional validation of miRNA target genes in the
physiological and pathological contexts may be guided
through current literature (e.g., see [31]).Cardiovascular Psychiatry and Neurology 3
“What causes changes in miRNA expression?” Unfortu-
nately, the underlying mechanisms of the ways and reasons
miRNAs become deregulated in disease (and speciﬁcally in
comorbid disease) remain largely unknown. It is possible
that accumulating genetic, cellular, or environmental insults,
for instance, during ageing, could aﬀect miRNA gene expres-
sion. Some of these eﬀects are perhaps governed themselves
by transcription and/or cellular factors, since miRNAs have
regulatory promoter regions and are transcribed mainly by
RNA polymerase II [43, 44]. An elegant study by Wang et al.
showed that, in myoblasts, the miR-29 promoter (and more
particularly the miR-29b-2/miR-29c cluster) is regulated by
thetranscriptionfactorsNFκBandYY1[45].Duringmyoge-
nesis, NFκB and YY1 downregulation causes derepression of
miR-29 that, in turn, accelerates diﬀerentiation by targeting
its repressor YY1. Whether this complex regulatory feedback
loop between miR-29, NFκB, and YY1 exists in neurons
remains to be explored. Interestingly, both NFκB and YY1
have been involved in BACE1 regulation [46, 47], and an
increase in YY1 expression was observed in human heart
failure [48]. It remains therefore an interesting hypothesis
that changes in NFκB and/or YY1 may contribute, at least
in part, to abnormal miR-29 expression in both the heart
and brain. It has been shown already that decreased miR-29
correlates with increased BACE1 in AD brain [31]. Whether
a similar correlation exists between NFκB/YY1 and BACE1
(andperhapsECMproteins)inthesecasesneedstobetested.
On this line of thought, it would be interesting to see if these
elements are aﬀected in the heart of these individuals, or
others, suﬀering from various heart conditions. It is worth
mentioning that NFκB seems also to be involved in the
regulation of miR-146a expression and could play a role in
the inﬂammation response in AD brain [49].
Secondary (downstream) eﬀects should also not be
ignored, as comorbidity may result from a primary disease.
Thislatterhypothesiscouldbetestedindisease-proneanimal
models, where, for example, excessive soluble amyloid-β
peptides produced in the brain of transgenic AD mouse
models could induce or modulate miRNA expression in the
heart.
4. Implicationsof the Hypothesis
These results could lead to the identiﬁcation of common
miRNAs and target genes/pathways involved in cooccurring
neurological and cardiovascular disorders. The use of RNA
interference and miRNA oligonucleotides into clinic could
help alleviate the risk for heart failure in patients suﬀering
from AD and possibly other neurodegenerative disorders.
Concretely, miR-29 mimics can be used to reduce cardiac
ﬁbrosis, thus providing an alternative method of maintain-
ing physiological levels of critical target genes of miR-29.
Cardiac ﬁbrosis results in stiﬀening of the heart, diminished
contractility, and abnormalities in cardiac conductance. A
beneﬁcial eﬀect of miR-29 mimics on BACE1 and amyloid-
β levels in the brain (and vascular system) is equally
envisaged. Reversing one or both of these processes could
therefore represent an important therapeutic target of MI
management and neurodegeneration. However, a word of
caution is needed especially with regard to unwanted oﬀ-
target eﬀects and the multiplicity of miRNA targets. Thus,
many optimization eﬀorts will be required before miRNAs
can be used into clinic.
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